{"389071":{"#nid":"389071","#data":{"type":"event","title":"Integrated Cancer Research Center Seminar","body":[{"value":"\u003Cp\u003E\u003Cstrong\u003E\u0022Opportunities to Improve Medulloblastoma Treatment Through New Insights Into Tumor Heterogeneity\u0022\u003Cbr \/\u003E\u003Cbr \/\u003ETobey J. MacDonald, M.D.\u003C\/strong\u003E\u003Cbr \/\u003E\u003Cstrong\u003EProfessor and Director\u003C\/strong\u003E\u003Cbr \/\u003E\u003Cstrong\u003EPediatric Brain Tumor Program\u003C\/strong\u003E\u003Cbr \/\u003E\u003Cstrong\u003EAflac Cancer \u0026amp; Blood Disorders Center\u003C\/strong\u003E\u003Cbr \/\u003E\u003Cstrong\u003EChildren\u0027s Healthcare of Atlanta\u003C\/strong\u003E\u003Cbr \/\u003E\u003Cstrong\u003EEmory University School of Medicine\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003EHeterogeneity Medulloblastoma (MB) is the most common malignant brain tumor in children. Standard treatment for MB includes the use of whole brain irradiation to protect against the development of metastasis. Despite this treatment, 30-40% of patients will eventually relapse with terminal metastatic disease, and for the majority of long-term survivors, the radiation therapy employed causes permanent and debilitating neuro-cognitive toxicity. Identifying more effective and less toxic therapy is thus critical for children diagnosed with MB. To achieve this goal, it will be necessary to decipher the complex molecular mechanisms that are essential for MB progression and metastasis to occur. Our lab first described high levels of the PDGFR gene in association with metastatic MB, and for the last decade we have been working on identifying additional key molecular alterations that together are essential for metastasis. Using mouse models of metastatic MB, we most recently found that some genetic changes, such as PDGFR, are present in both the primary and metastatic tumors, while others are confined to the metastases. We therefore hypothesize that \u201cmetastasis-driving\u201d molecular alterations emerge within a small subset of cells (\u201ccancer stem-like cells\u201d) within the primary tumor, but are only detectable once these cells are amplified by proliferation during the formation of the metastatic lesions. We thus believe that the cancer cell type and candidate genetic alterations essential for human MB metastasis can be identified by comparing the cells and genetic profiles of the primary tumors and their matched metastases obtained from the same individual in order to better tailor therapy for the prevention and treatment of metastasis.\u003C\/p\u003E","summary":null,"format":"limited_html"}],"field_subtitle":"","field_summary":[{"value":"\u003Cp\u003EGeorgia Tech has been a leader in the development of collaborative approaches to both cancer diagnostics and therapeutics. The mission of the Integrated Cancer Research Center (ICRC) is to facilitate integration of the diversity of technological, computational, scientific and medical expertise at Georgia Tech and partner institutions in a coordinated effort to develop improved cancer diagnostics and therapeutics.\u003C\/p\u003E","format":"limited_html"}],"field_summary_sentence":[{"value":"\u0022Opportunities to Improve Medulloblastoma Treatment Through New Insights Into Tumor Heterogeneity\u0022 - Tobey MacDonald, MD - Children\u0027s Healthcare of Atlanta, Emory University"}],"uid":"27195","created_gmt":"2015-03-20 08:12:37","changed_gmt":"2017-04-13 21:19:43","author":"Colly Mitchell","boilerplate_text":"","field_publication":"","field_article_url":"","field_event_time":{"event_time_start":"2015-04-21T17:00:00-04:00","event_time_end":"2015-04-21T18:00:00-04:00","event_time_end_last":"2015-04-21T18:00:00-04:00","gmt_time_start":"2015-04-21 21:00:00","gmt_time_end":"2015-04-21 22:00:00","gmt_time_end_last":"2015-04-21 22:00:00","rrule":null,"timezone":"America\/New_York"},"extras":[],"hg_media":{"361991":{"id":"361991","type":"image","title":"Integrated Cancer Research Center","body":null,"created":"1449245782","gmt_created":"2015-12-04 16:16:22","changed":"1475895098","gmt_changed":"2016-10-08 02:51:38","alt":"Integrated Cancer Research Center","file":{"fid":"201581","name":"icrc_logo_image_2014-square.jpg","image_path":"\/sites\/default\/files\/images\/icrc_logo_image_2014-square_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/icrc_logo_image_2014-square_0.jpg","mime":"image\/jpeg","size":3173213,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/icrc_logo_image_2014-square_0.jpg?itok=0Vt6IfQ_"}}},"media_ids":["361991"],"related_links":[{"url":"http:\/\/www.choa.org\/Childrens-Hospital-Services\/Cancer-and-Blood-Disorders\/Meet-the-Team\/Physicians-and-Researchers\/Tobey-J-MacDonald","title":"MacDonald profile"},{"url":"http:\/\/www.icrc.gatech.edu\/","title":"Integrated Cancer Research Center website"},{"url":"http:\/\/petitinstitute.gatech.edu\/icrc-seminars","title":"ICRC Seminar Series schedule"}],"groups":[{"id":"1254","name":"Wallace H. Coulter Dept. of Biomedical Engineering"},{"id":"1292","name":"Parker H. Petit Institute for Bioengineering and Bioscience (IBB)"}],"categories":[],"keywords":[{"id":"1808","name":"graduate students"},{"id":"248","name":"IBB"},{"id":"52061","name":"ICRC Seminar"}],"core_research_areas":[],"news_room_topics":[],"event_categories":[{"id":"1795","name":"Seminar\/Lecture\/Colloquium"}],"invited_audience":[{"id":"78751","name":"Undergraduate students"},{"id":"78761","name":"Faculty\/Staff"},{"id":"174045","name":"Graduate students"}],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003E\u003Ca href=\u0022mailto:john.mcdonald@biology.gatech.edu\u0022\u003EJohn McDonald, PhD\u003C\/a\u003E\u003C\/p\u003E","format":"limited_html"}],"email":[],"slides":[],"orientation":[],"userdata":""}}}